EP3189082A4 - Anti-pd-l1-konjugate zur behandlung von tumoren - Google Patents

Anti-pd-l1-konjugate zur behandlung von tumoren Download PDF

Info

Publication number: EP3189082A4
Authority: EP; European Patent Office
Prior art keywords: conjugates; treating tumors; tumors; treating
Prior art date: 2014-09-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP15839010.4A

Other languages

English (en)

French (fr)

Other versions

EP3189082B1 (de

EP3189082A1 (de

Inventor

Lixin Li

Walter LAU

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Birdie Biopharmaceuticals Inc Cayman Islands

Original Assignee

Birdie Biopharmaceuticals Inc Cayman Islands

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-01

Filing date

2015-08-29

Publication date

2018-04-04

2015-08-29 Application filed by Birdie Biopharmaceuticals Inc Cayman Islands filed Critical Birdie Biopharmaceuticals Inc Cayman Islands

2015-08-29 Priority to EP22199269.6A priority Critical patent/EP4148069A1/de

2015-08-29 Priority to EP20191420.7A priority patent/EP3763742B1/de

2017-07-12 Publication of EP3189082A1 publication Critical patent/EP3189082A1/de

2018-04-04 Publication of EP3189082A4 publication Critical patent/EP3189082A4/de

2020-08-19 Application granted granted Critical

2020-08-19 Publication of EP3189082B1 publication Critical patent/EP3189082B1/de

Status Active legal-status Critical Current

2035-08-29 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

EP15839010.4A 2014-09-01 2015-08-29 Anti-pd-l1-konjugate zur behandlung von tumoren Active EP3189082B1 (de)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
EP22199269.6A EP4148069A1 (de)	2014-09-01	2015-08-29	Anti-pd-l1-konjugate zur behandlung von tumoren
EP20191420.7A EP3763742B1 (de)	2014-09-01	2015-08-29	Anti-pd-l1-konjugate zur behandlung von tumoren

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN201410440824.0A CN105440135A (zh)	2014-09-01	2014-09-01	用于治疗肿瘤的抗-pd-l1结合物
PCT/CN2015/088456 WO2016034085A1 (en)	2014-09-01	2015-08-29	Anti-pd-l1 conjugates for treating tumors

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
EP22199269.6A Division EP4148069A1 (de)	2014-09-01	2015-08-29	Anti-pd-l1-konjugate zur behandlung von tumoren
EP20191420.7A Division EP3763742B1 (de)	2014-09-01	2015-08-29	Anti-pd-l1-konjugate zur behandlung von tumoren

Publications (3)

Publication Number	Publication Date
EP3189082A1 EP3189082A1 (de)	2017-07-12
EP3189082A4 true EP3189082A4 (de)	2018-04-04
EP3189082B1 EP3189082B1 (de)	2020-08-19

Family

ID=55439131

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP22199269.6A Withdrawn EP4148069A1 (de)	2014-09-01	2015-08-29	Anti-pd-l1-konjugate zur behandlung von tumoren
EP20191420.7A Active EP3763742B1 (de)	2014-09-01	2015-08-29	Anti-pd-l1-konjugate zur behandlung von tumoren
EP15839010.4A Active EP3189082B1 (de)	2014-09-01	2015-08-29	Anti-pd-l1-konjugate zur behandlung von tumoren

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
EP22199269.6A Withdrawn EP4148069A1 (de)	2014-09-01	2015-08-29	Anti-pd-l1-konjugate zur behandlung von tumoren
EP20191420.7A Active EP3763742B1 (de)	2014-09-01	2015-08-29	Anti-pd-l1-konjugate zur behandlung von tumoren

Country Status (10)

Country	Link
US (2)	US11130812B2 (de)
EP (3)	EP4148069A1 (de)
JP (1)	JP6921745B2 (de)
KR (1)	KR20170072192A (de)
CN (4)	CN112546238A (de)
AU (2)	AU2015311400B2 (de)
CA (1)	CA2959564A1 (de)
DK (1)	DK3189082T3 (de)
ES (1)	ES2822560T3 (de)
WO (1)	WO2016034085A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ717213A (en)	2008-12-09	2017-10-27	Genentech Inc	Anti-pd-l1 antibodies and their use to enhance t-cell function
CN112587658A (zh)	2012-07-18	2021-04-02	博笛生物科技有限公司	癌症的靶向免疫治疗
JP2017503803A (ja)	2014-01-10	2017-02-02	シャンハイバーディーバイオテックインコーポレイテッド	Ｅｇｆｒ発現腫瘍を処置するための化合物及び組成物
KR20160146747A (ko)	2014-03-31	2016-12-21	제넨테크, 인크.	항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
EP3166976B1 (de)	2014-07-09	2022-02-23	Birdie Biopharmaceuticals Inc.	Anti-pd-l1-kombinationen zur tumorbehandlung
CN112546238A (zh)	2014-09-01	2021-03-26	博笛生物科技有限公司	用于治疗肿瘤的抗-pd-l1结合物
KR20170135860A (ko)	2015-03-13	2017-12-08	싸이톰스 테라퓨틱스, 인크.	항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법
JP6797137B2 (ja)	2015-05-29	2020-12-09	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｏｘ４０に対する抗体およびその使用
JP6876629B2 (ja) *	2015-06-16	2021-05-26	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	Ｐｄ−ｌ１アンタゴニスト併用療法
MX377305B (es)	2015-09-14	2025-03-07	Pfizer	DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2.
MY198560A (en)	2015-10-02	2023-09-05	Hoffmann La Roche	Bispecific antibodies specific for a costimulatory tnf receptor
EP3368092B9 (de)	2015-10-29	2020-07-29	Novartis AG	Antikörperkonjugate mit toll-like-rezeptoragonist
WO2017106453A1 (en)	2015-12-17	2017-06-22	University Of Maryland, Baltimore County	A recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression
CN106943598A (zh)	2016-01-07	2017-07-14	博笛生物科技（北京）有限公司	用于治疗肿瘤的抗-her2组合
CN106943596A (zh)	2016-01-07	2017-07-14	博笛生物科技（北京）有限公司	用于治疗肿瘤的抗-cd20组合
CN106943597A (zh)	2016-01-07	2017-07-14	博笛生物科技（北京）有限公司	用于治疗肿瘤的抗-egfr组合
KR20180134395A (ko)	2016-04-19	2018-12-18	인네이트 튜머 이뮤니티, 인코포레이티드	Nlrp3 조정제
WO2017184735A1 (en)	2016-04-19	2017-10-26	Ifm Therapeutics, Inc	Nlrp3 modulators
JP7043425B2 (ja) *	2016-06-06	2022-03-29	ジェネンテック，インコーポレイテッド	シルベストロール抗体－薬物コンジュゲート及び使用方法
CN107574149B (zh) *	2016-07-05	2022-02-18	上海细胞治疗研究院	一种树突状细胞的促成熟方法及其用途
EP3484518B1 (de)	2016-07-07	2024-08-14	The Board of Trustees of the Leland Stanford Junior University	Antikörper-adjuvanzkonjugate
WO2018027204A1 (en)	2016-08-05	2018-02-08	Genentech, Inc.	Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
IL264999B2 (en) *	2016-08-23	2025-03-01	Univ Johns Hopkins	Antibody-activated nanoparticles for reprogrammed T-cell responses.
JP7206590B2 (ja)	2016-10-28	2023-01-18	東レ株式会社	癌の治療及び／又は予防用医薬組成物
TWI674261B (zh)	2017-02-17	2019-10-11	美商英能腫瘤免疫股份有限公司	Nlrp3 調節劑
CN108794467A (zh)	2017-04-27	2018-11-13	博笛生物科技有限公司	2-氨基-喹啉衍生物
AU2018264455B2 (en) *	2017-05-12	2024-12-12	Jiangsu Hengrui Medicine Co., Ltd.	Fusion protein containing TGF-beta receptor and medicinal uses thereof
JP2020522486A (ja)	2017-06-01	2020-07-30	サイトメックスセラピューティクスインコーポレイテッド	活性化可能抗ｐｄｌ１抗体、およびその使用方法
CA3067268A1 (en)	2017-06-23	2018-12-27	Birdie Biopharmaceuticals, Inc.	Crystalline resiquimod monosulfate anhydrate and its preparation and uses
WO2019084060A1 (en) *	2017-10-24	2019-05-02	Silverback Therapeutics, Inc.	CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
ES2946343T3 (es)	2018-03-23	2023-07-17	Lilly Co Eli	Anticuerpos anti-CD137 para combinación con anticuerpos anti-PD-L1
CN112041346B (zh) *	2018-03-23	2024-10-22	伊莱利利公司	用于与抗pd-1抗体组合的抗cd137抗体
EP4353235A3 (de)	2018-04-25	2024-07-31	Innate Tumor Immunity, Inc.	Nlrp3-modulatoren
EP3801634A4 (de) *	2018-06-04	2022-11-30	Trustees of Tufts College	Tumormikroumgebungsaktivierte wirkstoff-binder-konjugate und verwendungen davon
WO2020037091A1 (en)	2018-08-16	2020-02-20	Innate Tumor Immunity, Inc.	Imidazo[4,5-c]quinoline derived nlrp3-modulators
WO2020037092A1 (en)	2018-08-16	2020-02-20	Innate Tumor Immunity, Inc.	Imidazo[4,5-c]quinoline derived nlrp3-modulators
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
CN109897036B (zh) *	2019-03-15	2021-07-30	沈阳药科大学	三唑并吡啶类化合物及其制备方法和用途
WO2020190725A1 (en)	2019-03-15	2020-09-24	Bolt Biotherapeutics, Inc.	Immunoconjugates targeting her2
TWI833056B (zh)	2019-12-31	2024-02-21	財團法人工業技術研究院	核酸藥物複合體以及其用途
WO2021153981A1 (ko) *	2020-01-30	2021-08-05	성균관대학교산학협력단	면역관문 억제제 및 엑소좀 분비 억제제를 포함하는 항체-약물 접합체 및 이를 포함하는 약학적 조성물
EP4194010A4 (de) *	2020-08-04	2025-03-26	Progeneer Inc.	Konjugat aus einem funktionellen arzneimittel und einem toll-like-rezeptor-7- oder -8-agonisten mit temporär inaktivierter wirkstoffstelle und verwendung davon
US20240252670A1 (en) *	2021-05-13	2024-08-01	Tsinghua University	Antibody drug conjugate, preparation method therefor and application thereof
US20240391979A1 (en) *	2021-09-13	2024-11-28	Achelois Biopharma, Inc.	Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
IL318450A (en) *	2022-08-03	2025-03-01	Seagen Inc	Immunostimulatory ANTI-PD-L1-Drug conjugates
WO2024238588A2 (en) *	2023-05-15	2024-11-21	The Research Foundation For The State University Of New York	Targeted delivery of dual payload of mmaf or mmae and tlr7 agonists for the treatment of cancer
CN118286386A (zh) *	2024-04-09	2024-07-05	复旦大学附属中山医院	Nod1激动剂在制备治疗肝细胞癌药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013043647A1 (en) *	2011-09-19	2013-03-28	The Johns Hopkins University	Cancer immunotherapy
WO2014012479A1 (en) *	2012-07-18	2014-01-23	Shanghai Birdie Biotech, Inc.	Compounds for targeted immunotherapy

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL73534A (en)	1983-11-18	1990-12-23	Riker Laboratories Inc	1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4880935A (en)	1986-07-11	1989-11-14	Icrf (Patents) Limited	Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
IL89220A (en)	1988-02-11	1994-02-27	Bristol Myers Squibb Co	Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
AU634186B2 (en)	1988-11-11	1993-02-18	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6399754B1 (en)	1991-12-24	2002-06-04	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides
US6005087A (en)	1995-06-06	1999-12-21	Isis Pharmaceuticals, Inc.	2'-modified oligonucleotides
US5229275A (en)	1990-04-26	1993-07-20	Akzo N.V.	In-vitro method for producing antigen-specific human monoclonal antibodies
US5853984A (en)	1990-06-11	1998-12-29	Nexstar Pharmaceuticals, Inc.	Use of nucleic acid ligands in flow cytometry
US5660985A (en)	1990-06-11	1997-08-26	Nexstar Pharmaceuticals, Inc.	High affinity nucleic acid ligands containing modified nucleotides
US5874218A (en)	1990-06-11	1999-02-23	Nexstar Pharmaceuticals, Inc.	Method for detecting a target compound in a substance using a nucleic acid ligand
US5270163A (en)	1990-06-11	1993-12-14	University Research Corporation	Methods for identifying nucleic acid ligands
US6716580B2 (en)	1990-06-11	2004-04-06	Somalogic, Inc.	Method for the automated generation of nucleic acid ligands
US5763177A (en)	1990-06-11	1998-06-09	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6465189B1 (en)	1990-06-11	2002-10-15	Gilead Sciences, Inc.	Systematic evolution of ligands by exponential enrichment: blended selex
US5567588A (en)	1990-06-11	1996-10-22	University Research Corporation	Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5496938A (en)	1990-06-11	1996-03-05	Nexstar Pharmaceuticals, Inc.	Nucleic acid ligands to HIV-RT and HIV-1 rev
US6280932B1 (en)	1990-06-11	2001-08-28	Gilead Sciences, Inc.	High affinity nucleic acid ligands to lectins
EP1493825A3 (de)	1990-06-11	2005-02-09	Gilead Sciences, Inc.	Verfahren zur Herstellung von Nukleinsäureliganden
US5789163A (en)	1990-06-11	1998-08-04	Nexstar Pharmaceuticals, Inc.	Enzyme linked oligonucleotide assays (ELONAS)
US6001577A (en)	1998-06-08	1999-12-14	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
US5389640A (en)	1991-03-01	1995-02-14	Minnesota Mining And Manufacturing Company	1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
FI941572A7 (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US5226575A (en)	1991-11-21	1993-07-13	Scott Faust	Pneumatic mortar dispenser with flex release
US5622929A (en)	1992-01-23	1997-04-22	Bristol-Myers Squibb Company	Thioether conjugates
EP0625200B1 (de)	1992-02-06	2005-05-11	Chiron Corporation	Marker für krebs und biosynthetisches bindeprotein dafür
US6214345B1 (en)	1993-05-14	2001-04-10	Bristol-Myers Squibb Co.	Lysosomal enzyme-cleavable antitumor drug conjugates
US5352784A (en)	1993-07-15	1994-10-04	Minnesota Mining And Manufacturing Company	Fused cycloalkylimidazopyridines
US6458539B1 (en)	1993-09-17	2002-10-01	Somalogic, Inc.	Photoselection of nucleic acid ligands
US5798340A (en)	1993-09-17	1998-08-25	Gilead Sciences, Inc.	Nucleotide analogs
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5482936A (en)	1995-01-12	1996-01-09	Minnesota Mining And Manufacturing Company	Imidazo[4,5-C]quinoline amines
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5843732A (en)	1995-06-06	1998-12-01	Nexstar Pharmaceuticals, Inc.	Method and apparatus for determining consensus secondary structures for nucleic acid sequences
DE69626849T2 (de)	1995-12-22	2003-12-24	Bristol-Myers Squibb Co., Princeton	Verzweigte hydrazongruppen enthaltende kuppler
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
JP2001504448A (ja)	1996-08-30	2001-04-03	フュルステ，イェンス，ペーター	核酸の鏡面対称選択および進化
US6127533A (en)	1997-02-14	2000-10-03	Isis Pharmaceuticals, Inc.	2'-O-aminooxy-modified oligonucleotides
UA67760C2 (uk)	1997-12-11	2004-07-15	Міннесота Майнінг Енд Мануфакчурінг Компані	Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6242246B1 (en)	1997-12-15	2001-06-05	Somalogic, Inc.	Nucleic acid ligand diagnostic Biochip
US6110929A (en)	1998-07-28	2000-08-29	3M Innovative Properties Company	Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6403779B1 (en)	1999-01-08	2002-06-11	Isis Pharmaceuticals, Inc.	Regioselective synthesis of 2′-O-modified nucleosides
US20030054360A1 (en)	1999-01-19	2003-03-20	Larry Gold	Method and apparatus for the automated generation of nucleic acid ligands
US6451810B1 (en)	1999-06-10	2002-09-17	3M Innovative Properties Company	Amide substituted imidazoquinolines
US6331539B1 (en)	1999-06-10	2001-12-18	3M Innovative Properties Company	Sulfonamide and sulfamide substituted imidazoquinolines
BRPI0017590B8 (pt)	1999-06-25	2021-05-25	Genentech Inc	conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica
US6506887B1 (en)	1999-07-29	2003-01-14	Somalogic, Incorporated	Conditional-selex
US6635677B2 (en)	1999-08-13	2003-10-21	Case Western Reserve University	Methoxyamine combinations in the treatment of cancer
AU784062B2 (en)	1999-08-23	2006-01-19	Dana-Farber Cancer Institute, Inc.	Novel B7-4 molecules and uses therefor
IL147972A0 (en)	1999-08-23	2002-09-12	Dana Farber Cancer Inst Inc Ge	Pd-1, a receptor for b7-4 and uses therefor
US6803192B1 (en)	1999-11-30	2004-10-12	Mayo Foundation For Medical Education And Research	B7-H1, a novel immunoregulatory molecule
US20050032733A1 (en)	2001-05-18	2005-02-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US20050020525A1 (en)	2002-02-20	2005-01-27	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8202979B2 (en)	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US7097840B2 (en)	2000-03-16	2006-08-29	Genentech, Inc.	Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6376190B1 (en)	2000-09-22	2002-04-23	Somalogic, Inc.	Modified SELEX processes without purified protein
US6664264B2 (en)	2000-12-08	2003-12-16	3M Innovative Properties Company	Thioether substituted imidazoquinolines
UA74593C2 (en)	2000-12-08	2006-01-16	3M Innovative Properties Co	Substituted imidazopyridines
UA74852C2 (en)	2000-12-08	2006-02-15	3M Innovative Properties Co	Urea-substituted imidazoquinoline ethers
US20060057651A1 (en)	2000-12-08	2006-03-16	Bowdish Katherine S	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060142202A1 (en)	2000-12-08	2006-06-29	3M Innovative Properties Company	Compositions and methods for targeted delivery of immune response modifiers
EP2388590A1 (de)	2001-04-02	2011-11-23	Dana Farber Cancer Institute	PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
US20030175950A1 (en)	2001-05-29	2003-09-18	Mcswiggen James A.	RNA interference mediated inhibition of HIV gene expression using short interfering RNA
DE60140863D1 (de)	2001-06-10	2010-02-04	Noxxon Pharma Ag	Verwendung von L-Polynukleotiden zur diagnostischen Bilderzeugung
AU2775402A (en)	2001-06-29	2003-01-02	Medimolecular Pty Ltd	Nucleic acid ligands to complex targets
JP2005519990A (ja)	2001-10-12	2005-07-07	ユニバーシティオブアイオワリサーチファウンデーション	イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
JP4488740B2 (ja)	2001-11-13	2010-06-23	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	免疫細胞活性化を調節する作用剤およびその使用方法
DE60230340D1 (de)	2001-11-16	2009-01-22	3M Innovative Properties Co	N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
MXPA04004966A (es)	2001-11-27	2006-03-21	Anadys Pharmaceuticals Inc	Nucleosidos de 3-beta-d-ribofuranoziltiazol(4,5-d(pirimidina y uso de los mismos.
WO2003057145A2 (en)	2001-12-31	2003-07-17	Guilford Pharmaceuticals Inc.	SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
IL149820A0 (en)	2002-05-23	2002-11-10	Curetech Ltd	Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
WO2003105780A2 (en)	2002-06-18	2003-12-24	Epigenesis Pharmaceuticals, Inc.	A dry powder oligonucleotide formulation, preparation and its uses
PT1537878E (pt)	2002-07-03	2010-11-18	Ono Pharmaceutical Co	Composições de imunopotenciação
DK2357006T3 (en)	2002-07-31	2015-12-21	Seattle Genetics Inc	Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1413316A1 (de)	2002-09-27	2004-04-28	Bruno Robert	Bifunktionelle Konjugate oder Fusionsproteine
JP4511943B2 (ja)	2002-12-23	2010-07-28	ワイスエルエルシー	Ｐｄ−１に対する抗体およびその使用
KR20050114211A (ko)	2003-01-09	2005-12-05	아리제케 파마슈티칼즈 인크.	폐 질환의 치료 방법
US9259459B2 (en)	2003-01-31	2016-02-16	Celldex Therapeutics Inc.	Antibody vaccine conjugates and uses therefor
JP2006517974A (ja)	2003-02-13	2006-08-03	スリーエムイノベイティブプロパティズカンパニー	Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
EP2289559B1 (de)	2003-02-20	2014-02-12	Seattle Genetics, Inc.	Anti-CD70-Antikörper-Arzneimittelkonjugate und deren Verwendung zur Behandlung von Krebs und Immunerkrankungen
JP2007504232A (ja)	2003-09-05	2007-03-01	アナディスファーマシューティカルズインク	Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
AU2004280143A1 (en)	2003-10-11	2005-04-21	Tekmira Pharmaceuticals Corporation	Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
ITMI20032121A1 (it)	2003-11-04	2005-05-05	Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm	Procedimento per la preparazione di imiquimod e suoi intermedi
NZ583292A (en) *	2003-11-06	2012-03-30	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
US20050239735A1 (en)	2003-12-30	2005-10-27	3M Innovative Properties Company	Enhancement of immune responses
CN1938307B (zh)	2004-03-26	2010-06-16	大日本住友制药株式会社	9-取代的8-氧代腺嘌呤
JP2008506683A (ja) *	2004-07-18	2008-03-06	コーリーファーマシューティカルグループ，リミテッド	先天免疫応答を誘導するための方法および組成物
EP1791565B1 (de) *	2004-09-23	2016-04-20	Genentech, Inc.	Zystein-modifizierte Antikörper und Konjugate
CA2586913A1 (en)	2004-11-09	2006-05-18	University Of Southern California	Targeted innate immunity
SI1830876T1 (sl)	2004-12-30	2015-08-31	Meda Ab	Uporaba imikvimoda za zdravljenje kožnih metastaz, ki izhajajo iz rakavega tumorja dojke
US8067546B2 (en)	2005-04-19	2011-11-29	Seattle Genetics, Inc.	Humanized anti-CD70 binding agents and uses thereof
CN101355928B (zh)	2005-04-26	2013-05-22	卫材R&D管理株式会社	用于癌症免疫疗法的组合物和方法
EP2206501A3 (de)	2005-05-04	2010-09-29	Noxxon Pharma AG	HMGA bindende Nukleinsäuren
CN103059138B (zh)	2005-05-09	2015-10-28	小野药品工业株式会社	程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2007005874A2 (en)	2005-07-01	2007-01-11	Medarex, Inc.	Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US8871720B2 (en) *	2005-07-07	2014-10-28	Seattle Genetics, Inc.	Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
TW201402124A (zh)	2005-08-19	2014-01-16	Array Biopharma Inc	作為類鐸受體（ｔｏｌｌ-ｌｉｋｅｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
TWI382019B (zh)	2005-08-19	2013-01-11	Array Biopharma Inc	作為類鐸受體（ｔｏｌｌ-ｌｉｋｅｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
AU2006287416A1 (en) *	2005-09-07	2007-03-15	Medimmune, Llc	Toxin conjugated Eph receptor antibodies
CN101309933A (zh) *	2005-09-07	2008-11-19	米迪缪尼有限公司	毒素偶联的Eph受体抗体
EP1988896A4 (de)	2006-02-22	2011-07-27	3M Innovative Properties Co	Konjugate zur modifizierung von immunreaktionen
WO2007103048A2 (en)	2006-03-01	2007-09-13	Regents Of The University Of Colorado	Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US20080031887A1 (en)	2006-06-30	2008-02-07	Joseph Lustgarten	Conjugates for inducing targeted immune responses and methods of making and using same
JP2009542645A (ja)	2006-07-05	2009-12-03	アストラゼネカ・アクチエボラーグ	Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体
NZ576132A (en)	2006-10-27	2012-04-27	Genentech Inc	Antibodies and immunoconjugates and uses therefor
US20080149123A1 (en) *	2006-12-22	2008-06-26	Mckay William D	Particulate material dispensing hairbrush with combination bristles
US20080261913A1 (en)	2006-12-28	2008-10-23	Idenix Pharmaceuticals, Inc.	Compounds and pharmaceutical compositions for the treatment of liver disorders
TWI422594B (zh)	2007-02-02	2014-01-11	Baylor Res Inst	經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
DK2510946T3 (en)	2007-02-07	2015-11-02	Univ California	Conjugates of synthetic fluorescent agonists and their applications
EP3222634A1 (de)	2007-06-18	2017-09-27	Merck Sharp & Dohme B.V.	Antikörper zum humanen programmierten zelltod-pd-1-rezeptor
CN102317303A (zh)	2007-07-31	2012-01-11	约翰·霍普金斯大学	用于肿瘤或感染性疾病的免疫预防或免疫治疗的多肽-核酸偶联物
US20090304719A1 (en)	2007-08-22	2009-12-10	Patrick Daugherty	Activatable binding polypeptides and methods of identification and use thereof
DK2644192T3 (en)	2007-09-28	2017-06-26	Pfizer	Cancer cell targeting using nanoparticles
US8062852B2 (en)	2007-10-01	2011-11-22	The Children's Hospital And Regional Medical Center	Detection and treatment of autoimmune disorders
CN101909624A (zh)	2008-01-15	2010-12-08	麦达股份公司	用咪唑并喹啉衍生物治疗结肠病或预防结肠直肠癌
WO2009093250A2 (en)	2008-01-25	2009-07-30	Gavish-Galilee Bio Applications Ltd	Targeting of innate immune response to tumor site
MX2010008697A (es)	2008-02-07	2010-12-07	Univ California	Tratamiento de enfermedades de la vejiga con un activador de tlr7.
US8168757B2 (en)	2008-03-12	2012-05-01	Merck Sharp & Dohme Corp.	PD-1 binding proteins
EP2254571B1 (de)	2008-03-18	2015-07-01	Genentech, Inc.	Kombination aus einem anti-her2 antikörper-wirkstoff-konjugat und chemotherapeutika sowie verwendungsverfahren
US8552154B2 (en)	2008-09-26	2013-10-08	Emory University	Anti-PD-L1 antibodies and uses therefor
US8895702B2 (en)	2008-12-08	2014-11-25	City Of Hope	Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
DK2364314T3 (da)	2008-12-09	2014-05-12	Gilead Sciences Inc	Modulatorer af toll-lignende receptorer
JP5851842B2 (ja)	2009-01-12	2016-02-03	サイトムエックスセラピューティクス, インク.CytomX Therapeutics, Inc.	改変した抗体組成物、それを作製および使用する方法
ES2618573T3 (es)	2009-05-07	2017-06-21	ImmunoCellular Therapeutics,Ltd	Epítopos de CD133
LT2504364T (lt)	2009-11-24	2017-11-10	Medimmune Limited	Tiksliniai surišantys agentai prieš b7-h1
TWI506035B (zh)	2010-08-13	2015-11-01	Baylor Res Inst	以直接針對抗原呈現細胞之抗體的標靶佐劑為主之新穎疫苗佐劑
BR112013014316A2 (pt)	2010-12-09	2016-09-27	Genentech Inc	tratamento de câncer her2-positivo com paclitaxel e trastuzumabe-mcc-dm1
US9266533B2 (en) *	2010-12-30	2016-02-23	Institute Of Automation, Chinese Academy Of Sciences	Adaptive cruise control system and method for vehicle
CN106518851A (zh)	2011-01-12	2017-03-22	帆德制药股份有限公司	作为toll样受体调节剂的取代的苯并氮杂卓
WO2012122396A1 (en)	2011-03-08	2012-09-13	Baylor Research Institute	Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
PT2699264T (pt)	2011-04-20	2018-05-23	Medimmune Llc	Anticorpos e outras moléculas que ligam b7-h1 e pd-1
TWI557121B (zh)	2011-04-21	2016-11-11	原真股份有限公司	新穎激酶抑制劑
US8728486B2 (en)	2011-05-18	2014-05-20	University Of Kansas	Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
WO2013014668A1 (en)	2011-07-24	2013-01-31	Curetech Ltd.	Variants of humanized immunomodulatory monoclonal antibodies
WO2013019906A1 (en) *	2011-08-01	2013-02-07	Genentech, Inc.	Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
CN103748084B (zh)	2011-08-11	2016-07-06	亨斯迈先进材料美国有限责任公司	制备苯并噁嗪化合物的方法
WO2013063290A1 (en)	2011-10-25	2013-05-02	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN104661683A (zh) *	2011-11-09	2015-05-27	埃森德生物制药有限公司	免疫调节缀合物
ES2808152T3 (es)	2011-11-28	2021-02-25	Merck Patent Gmbh	Anticuerpos anti-PD-L1 y usos de los mismos
WO2013166110A1 (en)	2012-05-02	2013-11-07	Yale University	Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
JP6403166B2 (ja) *	2012-08-03	2018-10-10	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法
UA118251C2 (uk) *	2012-08-23	2018-12-26	Ейдженсіс, Інк.	Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 158p1d7
US9637491B2 (en)	2012-10-19	2017-05-02	Origenis Gmbh	Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
US10000482B2 (en)	2012-10-19	2018-06-19	Origenis Gmbh	Kinase inhibitors
JP2017503803A (ja)	2014-01-10	2017-02-02	シャンハイバーディーバイオテックインコーポレイテッド	Ｅｇｆｒ発現腫瘍を処置するための化合物及び組成物
CN105233291A (zh)	2014-07-09	2016-01-13	博笛生物科技有限公司	用于治疗癌症的联合治疗组合物和联合治疗方法
EP3166976B1 (de)	2014-07-09	2022-02-23	Birdie Biopharmaceuticals Inc.	Anti-pd-l1-kombinationen zur tumorbehandlung
CN112546238A (zh)	2014-09-01	2021-03-26	博笛生物科技有限公司	用于治疗肿瘤的抗-pd-l1结合物
CN105732635A (zh)	2014-12-29	2016-07-06	南京明德新药研发股份有限公司	一类Toll样受体7激动剂
US10821127B2 (en)	2015-11-09	2020-11-03	Shaperon Inc.	Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient
CN106943596A (zh)	2016-01-07	2017-07-14	博笛生物科技（北京）有限公司	用于治疗肿瘤的抗-cd20组合
CN106943597A (zh)	2016-01-07	2017-07-14	博笛生物科技（北京）有限公司	用于治疗肿瘤的抗-egfr组合
CN106943598A (zh)	2016-01-07	2017-07-14	博笛生物科技（北京）有限公司	用于治疗肿瘤的抗-her2组合
CN108794467A (zh)	2017-04-27	2018-11-13	博笛生物科技有限公司	2-氨基-喹啉衍生物
CA3067268A1 (en)	2017-06-23	2018-12-27	Birdie Biopharmaceuticals, Inc.	Crystalline resiquimod monosulfate anhydrate and its preparation and uses
ES2963112T3 (es)	2018-09-07	2024-03-25	Birdie Biopharmaceuticals Inc	Compuestos de imidazoquinolina y usos de los mismos
AU2019416031A1 (en)	2018-12-26	2021-07-15	Birdie Biopharmaceuticals, Inc.	Immune modulatory combinations and methods for treating cancers

2014
- 2014-09-01 CN CN202011353067.5A patent/CN112546238A/zh active Pending
- 2014-09-01 CN CN202011360594.9A patent/CN112587672A/zh active Pending
- 2014-09-01 CN CN201410440824.0A patent/CN105440135A/zh active Pending
2015
- 2015-08-29 CA CA2959564A patent/CA2959564A1/en active Pending
- 2015-08-29 JP JP2017530389A patent/JP6921745B2/ja not_active Expired - Fee Related
- 2015-08-29 AU AU2015311400A patent/AU2015311400B2/en not_active Ceased
- 2015-08-29 KR KR1020177008631A patent/KR20170072192A/ko not_active Ceased
- 2015-08-29 DK DK15839010.4T patent/DK3189082T3/da active
- 2015-08-29 EP EP22199269.6A patent/EP4148069A1/de not_active Withdrawn
- 2015-08-29 ES ES15839010T patent/ES2822560T3/es active Active
- 2015-08-29 WO PCT/CN2015/088456 patent/WO2016034085A1/en not_active Ceased
- 2015-08-29 EP EP20191420.7A patent/EP3763742B1/de active Active
- 2015-08-29 US US15/508,033 patent/US11130812B2/en not_active Expired - Fee Related
- 2015-08-29 EP EP15839010.4A patent/EP3189082B1/de active Active
- 2015-08-29 CN CN201580037746.2A patent/CN107074959A/zh active Pending
2021
- 2021-02-23 AU AU2021201166A patent/AU2021201166A1/en not_active Abandoned
- 2021-08-18 US US17/405,680 patent/US20220033503A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013043647A1 (en) *	2011-09-19	2013-03-28	The Johns Hopkins University	Cancer immunotherapy
WO2014012479A1 (en) *	2012-07-18	2014-01-23	Shanghai Birdie Biotech, Inc.	Compounds for targeted immunotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies", CANCER IMMUNOLOGY RESEARCH, vol. 3, no. 3, 1 March 2015 (2015-03-01), pages 288 - 295, XP009503020 *
See also references of WO2016034085A1 *

Also Published As

Publication number	Publication date
JP6921745B2 (ja)	2021-08-18
ES2822560T3 (es)	2021-05-04
US20170290923A1 (en)	2017-10-12
EP3763742A1 (de)	2021-01-13
JP2017530187A (ja)	2017-10-12
CN112587672A (zh)	2021-04-02
CA2959564A1 (en)	2016-03-10
EP3189082B1 (de)	2020-08-19
EP3763742B1 (de)	2022-10-05
CN107074959A (zh)	2017-08-18
US11130812B2 (en)	2021-09-28
CN112546238A (zh)	2021-03-26
CN105440135A (zh)	2016-03-30
AU2015311400B2 (en)	2021-04-01
US20220033503A1 (en)	2022-02-03
AU2015311400A1 (en)	2017-03-23
WO2016034085A1 (en)	2016-03-10
KR20170072192A (ko)	2017-06-26
EP4148069A1 (de)	2023-03-15
EP3189082A1 (de)	2017-07-12
AU2021201166A1 (en)	2021-03-11
DK3189082T3 (da)	2020-09-21

Legal Events

Date	Code	Title	Description
2017-03-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2017-06-15	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2017-06-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2017-07-12	17P	Request for examination filed	Effective date: 20170315
2017-07-12	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-07-12	AX	Request for extension of the european patent	Extension state: BA ME
2017-12-06	DAV	Request for validation of the european patent (deleted)
2017-12-06	DAX	Request for extension of the european patent (deleted)
2018-04-04	A4	Supplementary search report drawn up and despatched	Effective date: 20180301
2018-04-04	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/00 20060101ALI20180223BHEP Ipc: C07K 16/30 20060101AFI20180223BHEP Ipc: A61K 31/4745 20060101ALI20180223BHEP Ipc: A61K 31/4375 20060101ALI20180223BHEP Ipc: A61K 31/708 20060101ALI20180223BHEP Ipc: A61K 47/50 20170101ALI20180223BHEP Ipc: A61K 45/00 20060101ALI20180223BHEP
2018-06-01	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1240951 Country of ref document: HK
2019-04-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2019-05-15	17Q	First examination report despatched	Effective date: 20190411
2020-02-14	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602015057836 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C07K0016300000 Ipc: A61K0047680000
2020-02-27	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2020-02-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2020-03-25	INTG	Intention to grant announced	Effective date: 20200228
2020-03-25	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/00 20060101ALI20200214BHEP Ipc: A61K 31/4375 20060101ALI20200214BHEP Ipc: C07K 16/30 20060101ALI20200214BHEP Ipc: A61K 31/4745 20060101ALI20200214BHEP Ipc: A61K 45/00 20060101ALI20200214BHEP Ipc: A61K 47/68 20170101AFI20200214BHEP Ipc: A61K 31/708 20060101ALI20200214BHEP
2020-06-13	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2020-06-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2020-07-13	GRAR	Information related to intention to grant a patent recorded	Free format text: ORIGINAL CODE: EPIDOSNIGR71
2020-07-13	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2020-07-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2020-07-17	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2020-07-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2020-07-22	INTC	Intention to grant announced (deleted)
2020-08-19	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-08-19	INTG	Intention to grant announced	Effective date: 20200713
2020-08-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: VALIPAT S.A. C/O BOVARD SA NEUCHATEL, CH Ref country code: CH Ref legal event code: EP
2020-09-10	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602015057836 Country of ref document: DE
2020-09-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1303193 Country of ref document: AT Kind code of ref document: T Effective date: 20200915
2020-09-16	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2020-09-21	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20200914
2020-09-30	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2020-10-13	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2021-01-11	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2021-01-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201221 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201119 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201119 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201120 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819
2021-02-26	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201219 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819
2021-04-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 1303193 Country of ref document: AT Kind code of ref document: T Effective date: 20200819
2021-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200829
2021-05-04	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2822560 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210504
2021-05-20	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602015057836 Country of ref document: DE
2021-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819
2021-06-25	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2021-06-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2021-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819
2021-07-28	26N	No opposition filed	Effective date: 20210520
2021-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819
2022-06-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819
2022-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819
2023-07-05	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230524
2023-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20230728 Year of fee payment: 9
2023-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20230726 Year of fee payment: 9 Ref country code: IE Payment date: 20230725 Year of fee payment: 9 Ref country code: GB Payment date: 20230720 Year of fee payment: 9 Ref country code: ES Payment date: 20230905 Year of fee payment: 9 Ref country code: CH Payment date: 20230902 Year of fee payment: 9 Ref country code: AT Payment date: 20230725 Year of fee payment: 9
2023-11-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20230726 Year of fee payment: 9 Ref country code: FR Payment date: 20230721 Year of fee payment: 9 Ref country code: DK Payment date: 20230814 Year of fee payment: 9 Ref country code: DE Payment date: 20230718 Year of fee payment: 9 Ref country code: BE Payment date: 20230728 Year of fee payment: 9
2025-03-01	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602015057836 Country of ref document: DE
2025-03-17	REG	Reference to a national code	Ref country code: DK Ref legal event code: EBP Effective date: 20240831
2025-03-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2025-04-01	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2025-04-02	REG	Reference to a national code	Ref country code: NL Ref legal event code: MM Effective date: 20240901
2025-04-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MM01 Ref document number: 1303193 Country of ref document: AT Kind code of ref document: T Effective date: 20240829
2025-04-23	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20240829
2025-04-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240829 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240831
2025-05-15	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240901
2025-06-26	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20240831
2025-07-09	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20250301
2025-07-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240829 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240831
2025-07-15	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240829 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240831
2025-07-18	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240831
2025-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240829
2025-10-02	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20251002
2025-10-09	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240830
2025-10-13	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240830

Publication	Publication Date	Title
HUS2500001I1 (hu)	2025-01-28	Antitestkészítmények daganatkezelésre
EP3189082A4 (de)	2018-04-04	Anti-pd-l1-konjugate zur behandlung von tumoren
EP3166976A4 (de)	2018-03-14	Anti-pd-l1-kombinationen zur tumorbehandlung
EP3180010A4 (de)	2018-06-20	Kombinationstherapie zur behandlung von krebs
EP3092254A4 (de)	2017-09-20	Verbindungen und zusammensetzungen zur behandlung von her2-positiven tumoren
EP3177292A4 (de)	2018-04-11	Verbindungen und verwendung zur behandlung von krebs
EP3220916A4 (de)	2018-07-11	Verfahren zur behandlung von krebs
EP3206688A4 (de)	2018-06-13	Verfahren zur behandlung von krebs
EP3110509A4 (de)	2017-11-01	Verfahren zur behandlung von krebs
IL249231A0 (en)	2017-02-28	Pharmaceutical combinations for cancer treatment
EP3200815A4 (de)	2018-04-25	Verfahren und zusammensetzungen zur behandlung von krebs
EP3193884A4 (de)	2018-06-20	Kombinationstherapie zur behandlung von krebs
IL246761A0 (en)	2016-08-31	Combined cancer treatment
EP3099297A4 (de)	2017-06-07	Neuartiges verfahren zur behandlung von krebs
EP3268046A4 (de)	2018-11-21	Konjugate zur behandlung einer erkrankung
GB201413942D0 (en)	2014-09-17	Peptides useful for treating cancer
EP3193879A4 (de)	2018-05-16	Injizierbare formulierungen zur behandlung von krebs
EP3194625A4 (de)	2018-04-25	Kit zur krebsdetektion
EP3160591A4 (de)	2018-04-04	Zusammensetzungen und verfahren zur behandlung von krebs
HK40015031A (en)	2020-08-28	Methods for treating cancer
HK1262621A1 (en)	2020-01-17	Methods for treating cancer
HK1262818A1 (en)	2020-01-17	Methods for treating cancer
HK40001826A (en)	2020-03-13	Methods for treating cancer
HK40000087A (en)	2020-01-31	Methods for treating cancer
HK1237673A1 (en)	2018-04-20	Combinations for treating cancers